BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taguchi K. Pharmaceutical Technology Innovation Strategy Based on the Function of Blood Transport Proteins as DDS Carriers for the Treatment of Intractable Disorders and Cancer. Biol Pharm Bull 2020;43:1815-22. [PMID: 33268699 DOI: 10.1248/bpb.b20-00668] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Ou W, Wang J, Ren G, Bai L, Zhang B, Zhang W. The Innovation Strategy of State Grid APP Based on Internet+. 2022 World Automation Congress (WAC) 2022. [DOI: 10.23919/wac55640.2022.9934737] [Reference Citation Analysis]
2 Suzuki Y, Taguchi K, Kure T, Enoki Y, Otagiri M, Sakai H, Matsumoto K. Liposomal methemoglobin as a potent antidote for hydrogen sulfide poisoning. Toxicol Appl Pharmacol 2022;450:116159. [PMID: 35803436 DOI: 10.1016/j.taap.2022.116159] [Reference Citation Analysis]
3 Taguchi K, Suzuki Y, Tsutsuura M, Hiraoka K, Watabe Y, Enoki Y, Otagiri M, Sakai H, Matsumoto K. Liposomal Artificial Red Blood Cell-Based Carbon Monoxide Donor Is a Potent Renoprotectant against Cisplatin-Induced Acute Kidney Injury. Pharmaceutics 2021;14:57. [PMID: 35056952 DOI: 10.3390/pharmaceutics14010057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Taguchi K. Development of a bioactive gas delivery strategy based on biomimetic red blood cells for the treatment of intractable diseases. Official Journal of the Japan Society of Drug Delivery System 2021;36:300-306. [DOI: 10.2745/dds.36.300] [Reference Citation Analysis]
5 Taguchi K, Okamoto Y, Matsumoto K, Otagiri M, Chuang VTG. When Albumin Meets Liposomes: A Feasible Drug Carrier for Biomedical Applications. Pharmaceuticals (Basel) 2021;14:296. [PMID: 33810483 DOI: 10.3390/ph14040296] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]